Christopher Lawrence Carroll

USPTO Granted Patents = 21 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 8.1

ph-index = 6

Forward Citations = 95(Granted Patents)

Company Filing History:

19 out of 5,444

University of Texas System

patents

7 out of 7

Chempartner Corporation

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12186324 - Imidazopiperazine inhibitors of transcription activating proteins (2025-01-07),

2. 11958849 - GLS1 inhibitors for treating disease (2024-04-16),

3. 11945815 - PTPN11 inhibitors (2024-04-02),

4. 11434233 - Heterocyclic inhibitors of ATR kinase (2022-09-06),

5. 11370786 - GLS1 inhibitors for treating disease (2022-06-28),

6. 11104675 - PTPN11 inhibitors (2021-08-31),

7. 11058688 - Imidazopiperazine inhibitors of transcription activating proteins (2021-07-13),

8. 11001594 - Heterocyclic modulators of HIF activity for treatment of disease (2021-05-11),

9. 10899769 - Imidazopiperazinone inhibitors of transcription activating proteins (2021-01-26),

10. 10894052 - Heterocyclic inhibitors of ATR kinase (2021-01-19),

11. 10800774 - Heterocyclic inhibitors of ATR kinase (2020-10-13),

12. 10800769 - Heterocyclic inhibitors of ATR kinase (2020-10-13),

13. 10766892 - GLS1 inhibitors for treating disease (2020-09-08),

14. 10745420 - Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase (2020-08-18),

15. 10421765 - Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase (2019-09-24),

Title: The Inventor Spotlight: Christopher Lawrence Carroll

Introduction:

Christopher Lawrence Carroll, a talented inventor based in Houston, TX, has made significant contributions to the field of medicine with his innovative patented technologies. With a total of 19 patents to his name, Carroll's work has the potential to revolutionize the treatment and prevention of various diseases, particularly cancer.

Latest Patents:

1. GLS1 inhibitors for treating disease: Carroll's patented compounds and compositions show promising results in treating GLS1 mediated diseases, including cancer. The unique structure of Formula I sets these inhibitors apart, offering new possibilities for combating deadly illnesses.

2. Heterocyclic inhibitors of ATR kinase: Another breakthrough from Carroll, these compounds serve as inhibitors of ATR kinase, showcasing potential for cancer treatment and prevention. This cutting-edge approach demonstrates Carroll's commitment to pushing the boundaries of medical innovation.

Career Highlights:

Carroll has worked with prestigious institutions and corporations, including the University of Texas System and Chempartner Corporation. His tenure at these organizations has provided him with a platform to develop and refine his groundbreaking inventions, establishing him as a leading figure in the field of biomedical research and development.

Collaborations:

Throughout his career, Carroll has collaborated with esteemed professionals in the industry. Notable coworkers such as Philip Jones and Maria Emilia Di Francesco have contributed to the success of his projects, fostering a collaborative environment that nurtures innovation and creativity.

Conclusion:

Christopher Lawrence Carroll's impressive track record of patents and collaborations underscores his commitment to advancing medical science through groundbreaking inventions. His work holds great promise for the future of healthcare, offering hope to patients and clinicians alike. As he continues to push the boundaries of innovation, Carroll remains a visionary in the field, dedicated to improving the lives of individuals affected by serious illnesses.

This text is generated by artificial intelligence and may not be accurate.